We have read with interest the article by Vega et al. about the impact of CD44 expression on survival of neuroblastoma patients [@bib0001]. We had major concerns about the survival analyses showed in this manuscript.

By doing the analyses using the same public dataset (GSE45547) [@bib0002] and the R2 analysis platform (<http://r2.amc.nl>), we uncovered that: (1) the survival curves presented in this paper have been obtained taking into account all neuroblastoma stages, and not only stage 4 patients; (2) for panel d (i), the correct raw p-value is 0.048 and not 0.018; (3) the authors did not used the true top 10% cases with the highest CD44 expression nor a minimal group of 8 patients as they claim. For all stages and MYCN amplified cases, only one cut-off in the number of patients per group provides a significant raw p-value (R2 analysis) and this cut-off has likely been selected by the authors to draw their conclusions; (4) the indicated p-values are raw p-values but not Bonferroni corrected values as indicated. Corrected p-values are all not significant. Using the indicated criteria, we got no significant Bonferroni corrected p-values for the three categories of patients ([Fig. 1](#fig0001){ref-type="fig"}a, b and c). Strikingly, for all stages, when considering the top 10% cases with the lowest CD44 expression a significant Bonferroni corrected p-value was observed, indicating that low CD44 expression may be associated with poor survival ([Fig. 1](#fig0001){ref-type="fig"}d).Fig. 1(a, b, c and d) Survival curves for all patients with high or low CD44 expression in the indicated populations. In a and c the top 10% cases with the highest CD44 expression were considered, in all stages and in all stages without *MYCN* amplification, respectively. In b, the 8 cases with the highest CD44 expression were considered among all stages with *MYCN* amplification. In d, the top 10% cases with the lowest CD44 expression were considered in all stages. (e, f and g) Survival curves for the subset of stage 4 patients with high or low CD44 expression in the indicated populations. In e and g, the top 10% cases with the highest CD44 expression were considered; In f, the 8 cases with the highest CD44 expression were considered among stage 4 patients with *MYCN* amplification.Fig 1

Survival analysis performed specifically in stage 4 patients using the same criteria shows that CD44 expression is not of prognosis significance for overall survival ([Fig. 1](#fig0001){ref-type="fig"}e, [1](#fig0001){ref-type="fig"}f and [1](#fig0001){ref-type="fig"}g).

In conclusion, our analyses clearly indicate that CD44 expression is not a biomarker of prognostic value for high-risk stage 4 neuroblastoma patients.
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